REPROCELL Revenue and Competitors

REPROCELL Inc. was established in 2003 with the goal of contributing to people's health and welfare through the development of stem cell technologies. It was the first stem cell company in Japan. Today the company has evolved and become more international through global acquisitions. The corporate mission is defined as "improving human health through biomedical innovation and discovery". REPROCELL's Discovery business unit supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and predictive drug discovery custom services (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models, cell differentiation and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, REPROCELL labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL is currently in the planning phases for launching a mesenchymal stem cell-based clinical trial in Japan. REPROCELL went public on the Japan JASDAQ (Mothers Market) in June 2013. Stemgent, BioServe, Reinnervate became parts of REPROCELL in 2014. Biopta was acquired in 2015. **** REPROCELL is now able to provide COVID-19 Samples to researchers across the globe, including: • Serum, Plasma and whole blood • Convalescent plasma • Longitudinal collections from active and recovered patients • Nasal Swabs • Negative Control serum/ plasma